热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　里昂发布研报称，药明合联（02268）去年下半年收入和调整后净利润分别同比增长111%和227%，符合市场共识，并超出2025年1月发布的盈利预告。公司预计2025年收入增长35%（指引不变），调整后净利润率与2024年相近。该行将2025财年至2027财年的收入预测小幅调整0-1%，以反映2024年业绩的更新，将目标价从44.3港元上调至47.3港元，维持“跑赢大市评级”。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.